Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.

Seibel NL, Krailo M, Chen Z, Healey J, Breitfeld PP, Drachtman R, Greffe B, Nachman J, Nadel H, Sato JK, Meyers PA, Reaman GH.

Cancer. 2007 Apr 15;109(8):1646-53.

2.

Therapy for osteosarcoma: where do we go from here?

Chou AJ, Geller DS, Gorlick R.

Paediatr Drugs. 2008;10(5):315-27. Review.

PMID:
18754698
3.

Emerging role of weekly topotecan in recurrent small cell lung cancer.

Eckardt JR.

Oncologist. 2004;9 Suppl 6:25-32. Review.

4.

[Progress and stagnation in chemotherapy protocols for primary osteosarcoma].

Delépine N, Alkallaf S, Cornille H, Markowska B, Delépine G.

Ann Med Interne (Paris). 2003 Feb;154(1):12-24. Review. French.

PMID:
12746655
5.

Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.

Mori K, Ando K, Heymann D.

Expert Rev Anticancer Ther. 2008 Feb;8(2):151-9. doi: 10.1586/14737140.8.2.151. Review.

PMID:
18279055
6.

The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Xiao X, Wang W, Wang Z.

Paediatr Drugs. 2014 Dec;16(6):503-12. doi: 10.1007/s40272-014-0095-z. Review.

PMID:
25392156
7.

Topotecan in the treatment of recurrent small cell lung cancer: an update.

Ardizzoni A.

Oncologist. 2004;9 Suppl 6:4-13. Review.

8.

Primary bone osteosarcoma in the pediatric age: state of the art.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G.

Cancer Treat Rev. 2006 Oct;32(6):423-36. Epub 2006 Jul 24. Review.

PMID:
16860938
9.

Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.

Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID.

Cancer Treat Res. 1993;62:323-6. Review. No abstract available.

PMID:
8096746
10.

Treatment options for endometrial cancer: experience with topotecan.

Holloway RW.

Gynecol Oncol. 2003 Sep;90(3 Pt 2):S28-33. Review.

PMID:
13129493
11.

A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature.

Wodowski K, Hill DA, Pappo AS, Shochat SJ, Kun LE, Spunt SL.

J Pediatr Hematol Oncol. 2003 Jan;25(1):73-7. Review.

PMID:
12544778
12.

Osteosarcoma. Specific tumor management and results.

La Quaglia MP.

Chest Surg Clin N Am. 1998 Feb;8(1):77-95. Review.

PMID:
9515174
13.

Weekly topotecan in the management of ovarian cancer.

Morris RT.

Gynecol Oncol. 2003 Sep;90(3 Pt 2):S34-8. Review.

PMID:
13129494
14.

Controversies in the treatment of osteosarcoma.

Nachman JB.

Med J Aust. 1988 Apr 18;148(8):405-10. Review.

PMID:
3282156
15.

Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma.

Nardin A, Lefebvre ML, Labroquère K, Faure O, Abastado JP.

Curr Cancer Drug Targets. 2006 Mar;6(2):123-33. Review.

PMID:
16529542
16.

Management of osteosarcoma pulmonary metastases.

Harting MT, Blakely ML.

Semin Pediatr Surg. 2006 Feb;15(1):25-9. Review.

PMID:
16458843
17.

Topotecan in the management of cervical cancer.

Randall-Whitis LM, Monk BJ.

Expert Opin Pharmacother. 2007 Feb;8(2):227-36. Review.

PMID:
17257092
18.

Children's Oncology Group's 2013 blueprint for research: bone tumors.

Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N; COG Bone Tumor Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):1009-15. doi: 10.1002/pbc.24429. Epub 2012 Dec 19. Review.

19.

Delaying surgery with chemotherapy for osteosarcoma of the extremities.

Bielack SS, Machatschek JN, Flege S, Jürgens H.

Expert Opin Pharmacother. 2004 Jun;5(6):1243-56. Review.

PMID:
15163270
20.

Spontaneous regression of lung metastases from osteosarcoma.

Ogihara Y, Takeda K, Yanagawa T, Hirasawa Y.

Cancer. 1994 Nov 15;74(10):2798-803. Review.

Items per page

Supplemental Content

Write to the Help Desk